Live Analyst Rating Changes 38941 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Evie Koslosky
GS

Evie Koslosky

Goldman Sachs
Wall Street Analyst
★★★☆☆
#1785
on 13Foresight · ranked by our own returns
62%
Success Rate
+7.2%
Average Return
28 of 45 calls profitable · -381.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 62% of Evie Koslosky's ratings turned a profit when each position was held for 1 year — averaging +7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

32 Buy 16 Hold 5 Sell
Evie's Stock Coverage 14 ratings · 2026-10-08
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GRAL
GRAIL Inc
 Oct 05, 2026 HOLD Strong Buy
-25.7% avg upside
9 analysts
$120.00
9.28% Downside
 · ·
DHR
Danaher
 Oct 05, 2026 BUY Strong Buy
-0.6% avg upside
47 analysts
$250.00
15.87% Upside
 -2.5% ·
ADPT
Adaptive Biotechnologies
 Sep 29, 2026 BUY Strong Buy
+0.9% avg upside
16 analysts
$35.00
33.65% Upside
 +3.7% ·
TEM
Tempus AI, Inc. Class A
 Sep 22, 2026 HOLD Strong Buy
-0.1% avg upside
24 analysts
$75.00
5.92% Upside
 -10.2% ·
RVTY
Revvity
 Sep 20, 2026 HOLD Buy
-22.6% avg upside
24 analysts
$140.00
6.78% Downside
 +4.2% ·
WAT
Waters
 Sep 20, 2026 BUY Strong Buy
-7.0% avg upside
31 analysts
$515.00
19.84% Upside
 +0.4% ·
NTRA
Natera
 Sep 20, 2026 HOLD Strong Buy
-13.1% avg upside
28 analysts
$375.00
3.49% Downside
 +5.4% ·
SHC
Sotera Health
 Sep 20, 2026 BUY Strong Buy
+22.2% avg upside
13 analysts
$24.00
32.77% Upside
 -2.4% ·
CAI
Caris Life Sciences, Inc.
 Sep 20, 2026 BUY Strong Buy
+4.2% avg upside
20 analysts
$35.00
32.14% Upside
 -10.3% ·
GH
Guardant Health
 Sep 20, 2026 BUY Strong Buy
+2.0% avg upside
32 analysts
$225.00
34.28% Upside
 -4.8% ·
A
Agilent
 Sep 20, 2026 BUY Strong Buy
-5.6% avg upside
34 analysts
$185.00
10.63% Upside
 +4.0% ·
BRKR
Bruker
 Sep 20, 2026 SELL Buy
+1.2% avg upside
22 analysts
$50.00
14.35% Downside
 -3.7% ·
MTD
Mettler-Toledo
 Sep 20, 2026 HOLD Buy
-20.0% avg upside
19 analysts
$1510.00
1.31% Downside
 +7.0% ·
TMO
Thermo Fisher
 Dec 09, 2025 BUY Strong Buy
-6.3% avg upside
40 analysts
$685.00
4.57% Upside
 +15.5% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Evie Koslosky — Frequently Asked Questions
How accurate are Evie Koslosky's stock ratings?
Based on the calls 13Foresight could measure, about 62% of Evie's ratings were profitable over a one-year hold, with an average return of +7.4% per rating, or +34.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Evie ranked on 13Foresight?
Evie Koslosky is currently ranked #1785 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Evie cover?
Evie most recently has ratings on GRAL, DHR, ADPT, TEM, RVTY, WAT, NTRA, SHC, CAI, GH, A, BRKR and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.